Key messagesRisk of myocardial infarction remains poorly understood in patients with PsA.Duration of PsA was significantly associated with future risk of myocardial infarction.Physicians should enquire about disease duration when assessing cardiovascular risk in patients with PsA.

Introduction
============

PsA is a chronic inflammatory arthropathy that is frequently associated with skin and/or nail psoriasis. In recent years, cutaneous psoriasis has been associated with increased risk of cardiovascular disease (CVD), in particular myocardial infarction (MI) \[[@rky011-B1]\]. However, data on the relationship between PsA and MI are less clear cut \[[@rky011-B2], [@rky011-B3]\]. Chronic systemic inflammation in psoriasis and PsA may hypothetically increase the risk of MI, because cumulative exposure to systemic low-grade inflammation has been associated with atherosclerotic CVD \[[@rky011-B4]\]. This suggests that a longer duration of inflammatory disease, such as PsA, might increase the risk of CVD, including MI. Therefore, features such as PsA disease duration, which are easily obtainable by interview or review of the patient history, might identify those at higher risk for CVD. Indeed, a small study of angiographic coronary artery disease in psoriasis, and larger studies in RA and diabetes, have demonstrated that patients with a longer duration of disease have a higher risk of CVD, but these studies were limited to either clinical coronary artery disease or non-population-based methods \[[@rky011-B5]\]. We therefore examined the effects of PsA duration on the risk of MI in a nationwide cohort study in Denmark.

Methods
=======

Data sources and study population
---------------------------------

Study approval was obtained from the Danish Data Protection Agency (ref. 2007-58-0015; int. ref. GEH-2014-018, I-Suite 02736), and approval from an ethics committee is not required for registry studies in Denmark. The study was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology recommendations \[[@rky011-B9]\].

The Danish health-care system is tax supported and provides access to general practitioners, specialists in private clinics and public hospitals for all citizens without charge. A permanent and unique civil registration number is given to each resident upon birth or migration. This number allows for unambiguous linkage at an individual level of a range of administrative registries and clinical databases \[[@rky011-B10]\]. This allows for complete and accurate information on all health-care consultations (e.g. diagnoses), pharmacy-dispensed prescriptions, vital statistics and socio-economic status. Data are encrypted and rendered anonymous when used for research purposes. Diagnoses are coded as International Classification of Diseases (ICD) codes, and pharmacotherapy according to the Anatomical Therapeutic Chemical classification. Hospital-administered pharmacotherapy is coded as treatment procedure \[Sundhedsv岥nets Klassifikationssystem (SKS)\] codes. The majority of prescriptions in Denmark are claimed at pharmacies; however, certain drugs, for example, systemic immunosuppressant agents (including biologics and MTX) are predominantly given directly from hospital clinics.

The present study comprised all adults (≥18 years) alive and resident in Denmark on 1 January 2008 (i.e. the study start date). All individuals were followed from the start of the study until 31 December 2012, death, migration or the occurrence of an end point, whichever came first. Patients were classified as having PsA if they had received a diagnosis (inpatient or ambulatory) of PsA (ICD-10 M07.0-3 or ICD-8 696.09) before the start of the study.

Pharmacotherapy, co-morbidity and socio-economic status
-------------------------------------------------------

We identified baseline pharmacotherapy 6 months before study inclusion for the following therapies: adalimumab, cholesterol-lowering drugs, ciclosporin, etanercept, infliximab, LEF, MTX, SSZ and systemic CSs. Certolizumab pegol, ustekinumab and golimumab were not marketed in Europe at the time of study initiation and were thus not included. We assessed baseline co-morbidity as those of the following conditions that occurred in the 5-year period before study inclusion: alcohol abuse, CVD, diabetes and hypertension. Cardiovascular disease was defined as a composite of selected medical conditions and revascularization procedures as previously described \[[@rky011-B14]\]. Diabetes was defined by either ICD-code or use of glucose-lowering drugs. Collection of data on hypertension, smoking and alcohol abuse has been described elsewhere \[[@rky011-B15]\]. Socio-economic status was calculated as age-standardized quintiles of the average 5-year gross annual income at baseline.

Statistical analysis
--------------------

SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. The duration of PsA was calculated as the time difference between PsA onset and study start. Incidence rates were summarized per 1000 person-years, and Cox regression analyses were performed to estimate hazard ratios (HRs). In multivariable models, we adjusted for age, sex, socio-economic status, cholesterol-lowering drugs, smoking, alcohol abuse, diabetes, hypertension and CVD, respectively. We performed separate analyses, in which patients with previous MI were excluded. Sensitivity analyses were performed, with additional adjustment for use of systemic anti-PsA treatment and duration of cutaneous psoriasis, respectively. Patients were stratified based on whether they had PsA for \<2 years ('short duration') or ≥2 years ('long duration'). This cut-off has been established previously \[[@rky011-B18]\]. Model assumptions, including the linearity of continuous variables, absence of interactions and the proportional hazards assumptions, were tested and found to be valid unless otherwise specified. The proportional hazards assumptions were tested through significance tests and graphically assessed using log--log plots. Statistically significant results were defined as those with *P* \< 0.05, and we report results with 95% CIs were appropriate.

Results
=======

The study population comprised a total of 8071 patients with PsA and 4 348 857 general population control subjects ([Table 1](#rky011-T1){ref-type="table"}). Among patients with PsA, there was a slight (56%) female predominance, whereas the reference population had an equal gender distribution. Patients with PsA were slightly older (mean age 54.7 *vs* 48.7 years) at baseline and had a mean disease duration of 8 years. The prevalence of CVD, alcohol abuse, smoking and hypertension, respectively, was higher among patients with PsA, and a greater proportion of PsA patients had a received systemic treatment within the last 6 months before the start of the study compared with the reference population. Among patients with concurrent cutaneous psoriasis, the mean ([s]{.smallcaps}.[d]{.smallcaps}.) disease duration was 9.2 (7.7) and 4.3 (6.6) years for patients with PsA and the reference population, respectively. T[able]{.smallcaps} 1Baseline characteristics of the study populationCharacteristicsReference populationPsA population(*n* = 4 348 857)(*n* = 8071)Age, mean ([s]{.smallcaps}.[d]{.smallcaps}.), years48.7 (18.0)54.7 (14.0)Sex, *n* (%) Women2 208 599 (50.8)4517 (56.0) Men2 140 258 (49.2)3554 (44.0)Duration of PsA, mean ([s]{.smallcaps}.[d]{.smallcaps}.), yearsNA8.0 (7.0)Age at disease onset, mean ([s]{.smallcaps}.[d]{.smallcaps}.), yearsNA46.7 (13.8)Socio-economic status, *n* (%) Lowest870 786 (20.0)743 (9.2) Below average869 301 (20.0)2053 (25.4) Average869 276 (20.0)2071 (25.7) Above average869 680 (20.0)1667 (20.7) Highest869 814 (20.0)1537 (19.0)Smoking, *n* (%)430 808 (9.9)1316 (16.3)Co-morbidity, *n* (%) Alcohol abuse60 779 (1.4)145 (1.8) Cardiovascular disease378 124 (8.7)1252 (15.5) Diabetes157 384 (3.6)583 (7.2) Hypertension526 298 (12.1)1714 (21.2)Medication[^a^](#tblfn1){ref-type="table-fn"}, *n* (%) Adalimumab991 (0.0)199 (2.5) Cholesterol-lowering drugs399 843 (9.2)1294 (16.0) Ciclosporin1126 (0.0)47 (0.6) Biologics[^b^](#tblfn2){ref-type="table-fn"}943 (0.0)226 (2.8) Infliximab1224 (0.0)108 (1.3) LEF123 (0.0)8 (0.1) MTX15 224 (0.4)2028 (25.1) SSZ8874 (0.2)649 (8.0) Systemic CSs88 881 (2.0)776 (9.6)[^1][^2]

A total of 156 PsA patients and 54 215 control subjects experienced a MI during the study period. The incidence rates per 1000 person-years were 4.06 and 2.61 among patients with PsA and the reference population, respectively. Stratified by disease duration, the incidence rates were 2.15 and 4.59 among patients with short duration and long duration, respectively ([supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology Advances in Practice* online). There was a significant association between the duration of PsA and the risk of MI in crude (HR = 1.05; 95% CI: 1.04, 1.06) and adjusted (HR = 1.02; 95% CI: 1.01, 1.03) analyses, respectively ([Fig. 1](#rky011-F1){ref-type="fig"}). Stratified based on short and long disease duration, the adjusted HRs were 0.96 (95% CI: 0.60, 1.52; *P* = 0.8487) and 1.29 (95% CI: 1.09, 1.53; *P* = 0.0026), respectively. When patients with previous MI were excluded, that is, in analyses of first-time MI, the adjusted HR of MI associated with an additional year of disease duration was 1.02 (95% CI: 1.00, 1.03; *P* \< 0.05). In analyses stratified based on short and long disease duration, the adjusted results were 0.99 (95% CI: 0.61, 1.62; *P* = 0.9737) and 1.29 (95% CI: 1.07, 1.55; *P* = 0.0085) ([Table 2](#rky011-T2){ref-type="table"}). The results were not significantly altered by adjustment for systemic anti-PsA treatment (adjusted HR = 1.02; 95% CI: 1.01, 1.03) or the duration of cutaneous psoriasis (adjusted HR = 1.02, 95% CI: 1.00, 1.03; *P* \< 0.05), respectively. Other significant predictors of MI included older age, male sex, low socio-economic status, hypertension, diabetes, smoking, alcohol abuse, diabetes and previous CVD ([supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology Advances in Practice* online). T[able]{.smallcaps} 2Risk of myocardial infarction in patients with PsACrude HR (95% CI)*P*-valueAdjusted^a^ HR (95% CI)*P*-valueRisk of myocardial infarction (including patients with previous myocardial infarction)Duration of PsA, per year1.05 (1.04, 1.06)\<0.00011.02 (1.01, 1.03)0.0038Duration \<2 years0.82 (0.52, 1.31)0.40840.96 (0.60, 1.52)0.8487Duration ≥2 years1.76 (1.49, 2.08)\<0.00011.29 (1.09, 1.53)0.0026Risk of first-time myocardial infarctionDuration of PsA, per year1.05 (1.03, 1.06)\<0.00011.02 (1.00, 1.03)0.0131Duration \<2 years0.88 (0.54, 1.44)0.61730.99 (0.61, 1.62)0.9737Duration ≥2 years1.71 (1.41, 2.06)\<0.00011.29 (1.07, 1.55)0.0085[^3]

![Cumulative risk of myocardial infarction](rky011f1){#rky011-F1}

Discussion
==========

In this nationwide study of the Danish population, we observed a significantly increased risk of MI associated with the duration of PsA. Our results remained consistent in adjusted models and suggest that disease duration might be an easily obtainable risk marker when evaluating cardiovascular risk in patients with PsA, and possibly also in other inflammatory diseases. Traditional established MI risk factors, such as age, sex and lifestyle factors, were also significantly associated with the risk of MI, supporting the robustness of our findings.

Data suggest that cutaneous psoriasis lesions manifests on average 10 years before development of PsA \[[@rky011-B19]\]. Consequently, epidemiological studies tend to identify patients with a shorter duration of PsA compared with psoriasis. This might explain why the epidemiological data on the risk of CVD is not as consistent for PsA as for RA and psoriasis \[[@rky011-B2], [@rky011-B3]\]. Previously, studies of RA and diabetes have highlighted the importance of disease duration for the risk of CVD \[[@rky011-B5]\]. On the contrary, a small single-centre study found no relationship between increased duration of psoriasis and increased CVD risk \[[@rky011-B20]\], whereas a larger study found a significantly increased risk of CVD associated with duration of psoriasis \[[@rky011-B14]\].

Contrasting the present findings, one previous study \[[@rky011-B21]\] failed to find an association between disease duration and the extent of atherosclerosis among patients with PsA, albeit that only 44% of patients were seen in the clinic within the first 2 years after the diagnosis.

Certain limitations apply to the interpretation of our study results, the most important being the observational nature of our data. Indeed, observational studies cannot establish a causal relationship, and although our results are biologically plausible and remained consistent in a number of sub-analyses, the results should be considered hypothesis generating. Moreover, it is likely that some patients might not seek medical treatment in very early and mild stages of PsA, leading to an underestimation of the disease duration. We did not include adjustment for NSAIDs because these are also available over the counter in Denmark. Lastly, we lacked data on obesity/BMI and on clinical and radiographic findings, and whether differences in PsA severity might have affected our results remains unclear.

In conclusion, we observed an increased risk of MI associated with a longer duration of PsA. Our findings call for increased focus on disease duration in CVD risk assessment among patients with PsA.
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[^1]: ^a^Biologics include etanercept, infliximab, adalimumab, certolizumab pegol and golimumab. Certolizumab pegol, ustekinumab and golimumab were not marketed in Europe at the time of study start.

[^2]: ^b^Within the last 6 months. NA, not applicable.

[^3]: ^a^Adjusted for age, sex, socio-economic status, cholesterol-lowering drugs, smoking, alcohol abuse, diabetes, hypertension and previous cardiovascular disease. HR: hazard ratio.
